6-(4-Morpholino)-hexanon-(3) | 91016-86-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 6-(4-Morpholino)-hexanon-(3)
• 英文别名: 6-Morpholino-hexan-3-on；6-Morpholinohexan-2-on；6-morpholin-4-yl-hexan-3-one；6-Morpholin-4-ylhexan-3-one
• CAS: 91016-86-3
• 化学式: C₁₀H₁₉NO₂
• 分子量: 185.266
• InChiKey: PEZZVWURPYJSAJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  吗啉 、 hexa-1,5-dien-3-amine 在 chloro(1,5-cyclooctadiene)rhodium(I) dimer 、 1,3-双(二苯基膦)丙烷 、 silver(I) 4-methylbenzenesulfonate 作用下， 以 乙二醇二甲醚 为溶剂， 反应 24.0h， 以34%的产率得到1,6-dimorpholinohexan-3-amine
  参考文献：
  名称：

  Anti-Markovnikov Hydroamination of Homoallylic Amines

  摘要：

  The development of an anti-Markovnikov-selective hydroamination of unactivated alkenes is a significant challenge in organometallic chemistry. Herein, we present the rhodium-catalyzed anti-Markovnikov-selective hydroamination of homoallylic amines. The proximal Lewis basic amine serves to promote reactivity and enforce regioselectivity through the formation of the favored metallacycle, thus over-riding the inherent reactivity of the alkene. The scope of both the amine nudeophiles and homoallylic amines that participate in the reaction is demonstrated.

  DOI：

  10.1021/jacs.5b08500

文献信息

• Substituted Bicyclic Dihydropyrimidinones And Their Use As Inhibitors Of Neutrophil Elastase Activity
  申请人：GNAMM Christian

  公开号：US20140249129A1

  公开（公告）日：2014-09-04

  This invention relates to substituted bicyclic dihydropyrimidinones of formula 1 and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other autoimmune and allergic disorders, allograft rejection, and oncological diseases.

  这项发明涉及公式1的取代双环二氢嘧啶酮及其作为中性粒细胞弹性蛋白酶活性抑制剂的用途，包含这些化合物的药物组合物，以及将其用作治疗和/或预防肺部、胃肠道和泌尿系统疾病、皮肤和眼睛的炎症性疾病以及其他自身免疫和过敏性疾病、移植物排斥反应和肿瘤性疾病的方法。
• [EN] COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY<br/>[FR] COMPOSÉS POUR INHIBER L'ACTIVITÉ DE LA KINÉSINE KSP
  申请人：SCHERING CORP

  公开号：WO2009061595A1

  公开（公告）日：2009-05-14

  The present invention relates to compounds of Formula (I), below, (wherein R1, R2, R3, p, E, ring A, and ring B are as defined herein). The present invention also relates to compositions (including pharmaceutically acceptable compositions) comprising these compounds, alone and in combination with one or more additional therapeutic agents, and to methods for their use in inhibiting KSP kinesin activity, and for treating cellular proliferative diseases or disorders associated with KSP kinesin activity.

  本发明涉及以下式（I）的化合物（其中R1、R2、R3、p、E、环A和环B的定义如本文所述）。本发明还涉及包括这些化合物的组合物（包括药用合成物），单独或与一个或多个额外治疗剂结合使用的方法，以及用于抑制KSP动力蛋白活性和治疗与KSP动力蛋白活性相关的细胞增殖性疾病或紊乱的方法。
• [EN] SPIRO 1,3,4-THIADIAZOLINE DERIVATIVES AS KSP INHIBITORS<br/>[FR] DÉRIVÉS DE SPIRO 1,3,4-THIADIAZOLINE INHIBITEURS DE KSP
  申请人：SCHERING CORP

  公开号：WO2010132520A1

  公开（公告）日：2010-11-18

  The present invention relates to compounds of Formula (I), below, (wherein X, R1, R2, R3, p, ring A, and ring B are as defined herein). The present invention also relates to compositions (including pharmaceutically acceptable compositions) comprising these compounds, alone and in combination with one or more additional therapeutic agents, and to methods for their use in inhibiting KSP kinesin activity, and for treating cellular proliferative diseases or disorders associated with KSP kinesin activity.

  本发明涉及下式（I）的化合物（其中X、R1、R2、R3、p、环A和环B的定义如本文所述）。本发明还涉及包括这些化合物的组合物（包括药用组合物），单独或与一个或多个额外治疗剂结合使用的方法，以及用于抑制KSP肌动蛋白活性和治疗与KSP肌动蛋白活性相关的细胞增殖性疾病或疾病的方法。
• Compositions and methods for treating cardiovascular disease
  申请人：Genentech, Inc.

  公开号：US11034725B2

  公开（公告）日：2021-06-15

  The invention provides PCSK9 inhibitors, compositions comprising the PCSK9 inhibitors, and methods of identifying and using the PCSK9 inhibitors.

  本发明提供了 PCSK9 抑制剂、包含 PCSK9 抑制剂的组合物以及鉴定和使用 PCSK9 抑制剂的方法。
• COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE
  申请人：Genentech, Inc.

  公开号：US20200283478A1

  公开（公告）日：2020-09-10

  The invention provides PCSK9 inhibitors, compositions comprising the PCSK9 inhibitors, and methods of identifying and using the PCSK9 inhibitors.